- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01696968
Badania przesiewowe w kierunku raka płuc u starszych pacjentów (badanie przesiewowe PLCO)
Próba przesiewowa raka prostaty, płuc, jelita grubego i jajnika (PLCO).
This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for lung cancer.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
PRIMARY OBJECTIVES:
I. To determine whether screening with chest x-ray can reduce mortality from lung cancer in women and men aged 55-74 at entry.
SECONDARY OBJECTIVES:
I. To assess screening variables, other than mortality, for each of the interventions including sensitivity, specificity, and positive predictive value.
II. To assess the incidence, stage, and survival of cancer cases. III. To investigate the mortality predictive value of biologic and/or prognostic characterizations of tumor tissue as intermediate endpoints.
IV. To conduct biomolecular and genetic research into factors associated with cancer carcinogenesis and promotion, as well as the early detection of these factors.
OUTLINE: Participants in the overall PLCO study are stratified by screening center, gender, and age (55-59 vs 60-64 vs 65-69 vs 70-74). Participants are randomized to 1 of 2 arms (control vs screening).
ARM I (Control): Participants receive standard medical care. Participants complete a Diet History Questionnaire (DHQ) at baseline.
ARM II (Lung Screening): Participants undergo a chest x-ray (one postero-anterior view) at baseline and annually for 2 years. Participants classified as "smokers" undergo an additional chest x-ray at year 3. A scheduling and tracking procedure is implemented to ensure regular attendance at repeat screens for participants screened negative or for those who are designated suspicious or positive at screening but for whom subsequent diagnostic procedures do not reveal lung cancer (follow-up diagnostic procedures are through their own medical care environment). Participants diagnosed with lung cancer via a screening test are referred for treatment in accordance with current accepted practice for appropriate stage of disease, patient age, and medical condition; a procedure is provided for contact with qualified medical personnel to insure appropriate therapy.
Participants complete a Baseline Questionnaire (BQF/M) to assess smoking status. Participants complete a Dietary Questionnaire (DQX) at baseline and DHQ at year 3. An Annual Study Update (ADU) (previously referred to as the Periodic Survey of Health [PSH] questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident lung cancers as all deaths that occur among both screened and control subjects during the trial.
After completion of screening, participants are followed up for at least 13 years.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Maryland
-
Bethesda, Maryland, Stany Zjednoczone, 20892
- National Institutes of Health Clinical Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Exclusion Criteria:
-
Men and women who at the time of randomization are less than 55 or greater than or equal to 75 years of age
-
Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer
-
Individuals with known prior cancer of the colon, rectum, lung, prostate (men only) or ovary (women only)
- This includes primary or metastatic PLCO cancers
-
Individuals with previous surgical removal of the entire colon, one lung, or the entire prostate (men only)
- Until October 1996, women with previous surgical removal of both ovaries were excluded from the trial. In order to increase the enrollment of women into the trial, beginning in October 1996, these women were no longer excluded for this reason.
-
Individuals who are participating in another cancer screening or cancer primary prevention trial
-
Males who have taken Proscar/Propecia/finasteride in the past 6 months
- NOTE: Individuals who are already enrolled in the trial when their physician prescribes finasteride are not prevented from taking this medication. As a result, these participants will continue to be screened and followed just as those participants who are not on finasteride.
- NOTE: Men who are taking Tamoxifen are not excluded from any part of the PLCO Screening Trial.
- Prior to April 1, 1999 women were excluded from the trial if they were currently taking or had taken Tamoxifen or Evista\Raloxifene in the past 6 months. As of April 1999 based on a decision from the PLCO Ovary Subcommittee, women who have or are currently taking Tamoxifen or Evista\Raloxifene are not excluded from participation.
-
Individuals who are unwilling or unable to sign the informed consent form
-
Males who have had more than one PSA blood test in the past three years
-
Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past three years
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Ekranizacja
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Pojedynczy
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Brak interwencji: Control
Participants receive standard medical care. Participants complete a DHQ at baseline. |
|
|
Aktywny komparator: Lung Screening
Participants undergo a chest x-ray (one postero-anterior view) at baseline and annually for 2 years. Participants classified as "smokers" undergo an additional chest x-ray at year 3. Participants complete a BQF/M at baseline. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident lung cancers as all deaths that occur among both screened and control subjects during the trial. |
Undergo questionnaire assessments Undergo a chest x-ray
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Lung Cancer Deaths
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Lung cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Lung Cancer Death Rates
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Lung cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Deaths From All Causes
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Deaths from all causes were compared between the lung screening arm and the usual care arm. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Death Rates From All Causes
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Deaths from all causes were compared between the lung screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Lung Cancer Incidence
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Lung cancer diagnoses confirmed by medical record abstraction. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Lung Cancer Incidence Rates
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Lung cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as lung cancer diagnoses divided by person years at risk for lung cancer. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Complications of Diagnostic Evaluation Following a Positive Screening Test
Ramy czasowe: One year from screening examination
|
Number of positive screens with complications. |
One year from screening examination
|
|
T0 (Baseline) CXR Screening Results
Ramy czasowe: T0 (at study entry)
|
Postero-anterior view chest radiograph (CXR) result |
T0 (at study entry)
|
|
T1 CXR Screening Results
Ramy czasowe: T1 (one year after entry)
|
Postero-anterior view chest radiograph (CXR) result |
T1 (one year after entry)
|
|
T2 CXR Screening Results
Ramy czasowe: T2 (two years after entry)
|
Postero-anterior view chest radiograph (CXR) result |
T2 (two years after entry)
|
|
T3 CXR Screening Results
Ramy czasowe: T3 (three years after entry)
|
Postero-anterior view chest radiograph (CXR) result |
T3 (three years after entry)
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Christine D Berg, National Cancer Institute (NCI)
Publikacje i pomocne linki
Publikacje ogólne
- You D, Wang D, Wu Y, Chen X, Shao F, Wei Y, Zhang R, Lange T, Ma H, Xu H, Hu Z, Christiani DC, Shen H, Chen F, Zhao Y. Associations of genetic risk, BMI trajectories, and the risk of non-small cell lung cancer: a population-based cohort study. BMC Med. 2022 Jun 6;20(1):203. doi: 10.1186/s12916-022-02400-6.
- Jiang Y, Xie Q, Chen R. Breast Cancer Incidence and Mortality in Relation to Hormone Replacement Therapy Use Among Postmenopausal Women: Results From a Prospective Cohort Study. Clin Breast Cancer. 2022 Feb;22(2):e206-e213. doi: 10.1016/j.clbc.2021.06.010. Epub 2021 Jun 26.
- Wang K, Wu Q, Li Z, Reger MK, Xiong Y, Zhong G, Li Q, Zhang X, Li H, Foukakis T, Xiang T, Zhang J, Ren G. Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study. Clin Nutr. 2021 May;40(5):3370-3378. doi: 10.1016/j.clnu.2020.11.009. Epub 2020 Nov 16.
- Malcomson FC, Shams-White MM, Reedy J, Huang WY, Moore SC, Loftfield E. Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and risk of lifestyle-related cancers in the prostate, lung, colorectal, and ovarian cancer screening trial. BJC Rep. 2025 Nov 19;3(1):81. doi: 10.1038/s44276-025-00195-6.
- Fan Z, Zhang Y, Yao Q, Liu X, Duan H, Liu Y, Sheng C, Lyu Z, Yang L, Song F, Huang Y, Song F. Effects of joint screening for prostate, lung, colorectal, and ovarian cancer - results from a controlled trial. Front Oncol. 2024 Apr 29;14:1322044. doi: 10.3389/fonc.2024.1322044. eCollection 2024.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Szacowany)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Nowotwory według lokalizacji
- Nowotwory
- Choroby Układu Oddechowego
- Choroby płuc
- Nowotwory Układu Oddechowego
- Nowotwory klatki piersiowej
- Nowotwory płuc
- Zjawiska fizyczne
- Sprzęt i materiały eksploatacyjne
- Zjawiska elektromagnetyczne
- Zjawiska magnetyczne
- Promieniowanie elektromagnetyczne
- Promieniowanie
- Promieniowanie, jonizujące
- Promieniowanie rentgenowskie
- Phantoms, obrazowanie
Inne numery identyfikacyjne badania
- NCI-2012-01756
- NCI-2012-01756 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- CDR0000078532
- NCI-P93-0050
- PLCO-1
- PLCO-Lung (Inny identyfikator: National Cancer Institute)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .